Drugs /

ro7198457

Back to Drugs List

Overview

NCI Definition [1]:
An mRNA-based individualized, therapeutic cancer vaccine targeting an unspecified amount of tumor-associated antigens (TAAs) that are specifically expressed in the patient's cancer, with potential immunostimulatory and antineoplastic activities. Upon administration, the personalized cancer vaccine RO7198457 is taken up and translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses against cancer cells expressing the TAA(s).

Clinical Trials

View Clinical Trials for ro7198457

Ro7198457 has been investigated in 5 clinical trials, of which 4 are open and 1 is closed. Of the trials investigating ro7198457, 2 are phase 1 (2 open) and 3 are phase 2 (2 open).

Circulating Tumor-Derived DNA Positive, ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for ro7198457 clinical trials.

Acral lentiginous melanoma, breast carcinoma, and colorectal adenocarcinoma are the most common diseases being investigated in ro7198457 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ro7198457
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ro7198457
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ro7198457 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pcv ro7198457, personalized cancer vaccine ro7198457
NCIT ID [1]:
C140162

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.